|
| | |
|
Am J Psychiatry 1997; 154:782-791
Copyright © 1997 by American Psychiatric Association
Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group
DL Zimbroff, JM Kane, CA Tamminga, DG Daniel, RJ Mack, PJ Wozniak, TB Sebree, BA Wallin and KB Kashkin
Loma Linda University Medical School, Calif, USA.
OBJECTIVE: This multicenter, double-blind, placebo-controlled study
evaluated the efficacy and safety of three doses of sertindole (12, 20, and
24 mg/day) and haloperidol (4, 8, and 16 mg/day) in the treatment of
psychotic symptoms for 497 hospitalized patients with schizophrenia.
METHOD: The patients were randomly assigned to one of the medication groups
and received treatment for 8 weeks. Changes in Positive and Negative
Syndrome Scale, Scale for the Assessment of Negative Symptoms, Brief
Psychiatric Rating Scale, and Clinical Global Impression scores were used
as evaluations of treatment efficacy. Three rating scales were used to
assess extrapyramidal symptoms as well as the occurrence of adverse events
and the use of medications related to extrapyramidal symptoms. RESULTS:
Both sertindole and haloperidol were comparably effective in the treatment
of psychosis, and all dose levels were significantly more effective than
placebo. For the treatment of negative symptoms, only sertindole, 20
mg/day, was significantly more effective than placebo. For all
extrapyramidal symptom measures, sertindole was clinically and
statistically indistinguishable from placebo, and rates of extrapyramidal
symptoms were not dose related. All dose levels of haloperidol produced
significantly more extrapyramidal symptoms than placebo or sertindole.
Adverse events associated with sertindole treatment were mild in severity.
CONCLUSIONS: Sertindole is a new antipsychotic agent effective for the
treatment of both the positive and negative symptoms of schizophrenia, with
motor side effects that are indistinguishable from those associated with
placebo.
This article has been cited by other articles:
|
|
|
|
 
J. M. Stone, J. M. Davis, S. Leucht, and L. S. Pilowsky
Cortical Dopamine D2/D3 Receptors Are a Common Site of Action for Antipsychotic Drugs--An Original Patient Data Meta-analysis of the SPECT and PET In Vivo Receptor Imaging Literature
Schizophr Bull,
February 26, 2008;
(2008)
sbn009v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. M. Bratti, J. M. Kane, and S. R. Marder
Chronic Restlessness With Antipsychotics
Am J Psychiatry,
November 1, 2007;
164(11):
1648 - 1654.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Marder, S. M. Essock, A. L. Miller, R. W. Buchanan, D. E. Casey, J. M. Davis, J. M. Kane, J. A. Lieberman, N. R. Schooler, N. Covell, et al.
Physical Health Monitoring of Patients With Schizophrenia
Am J Psychiatry,
August 1, 2004;
161(8):
1334 - 1349.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Antzelevitch, L. Belardinelli, L. Wu, H. Fraser, A. C. Zygmunt, A. Burashnikov, J. M. Di Diego, J. M. Fish, J. M. Cordeiro, R. J. Goodrow Jr, et al.
Electrophysiologic Properties and Antiarrhythmic Actions of a Novel Antianginal Agent
Journal of Cardiovascular Pharmacology and Therapeutics,
March 1, 2004;
9(1_suppl):
S65 - S83.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. B. Thomsen, P. G. A. Volders, M. Stengl, R. L. H. M. G. Spaatjens, J. D. M. Beekman, U. Bischoff, M. A. Kall, K. Frederiksen, J. Matz, and M. A. Vos
Electrophysiological Safety of Sertindole in Dogs with Normal and Remodeled Hearts
J. Pharmacol. Exp. Ther.,
November 1, 2003;
307(2):
776 - 784.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Davis, N. Chen, and I. D. Glick
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Arch Gen Psychiatry,
June 1, 2003;
60(6):
553 - 564.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Weiden
The Creation of Psychopharmacology
Psychiatr Serv,
December 1, 2002;
53(12):
1639 - 1640.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. S. Cobb and E. D. Abercrombie
Distinct Roles for Nigral GABA and Glutamate Receptors in the Regulation of Dendritic Dopamine Release under Normal Conditions and in Response to Systemic Haloperidol
J. Neurosci.,
February 15, 2002;
22(4):
1407 - 1413.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Eckardt, G. Breithardt, and W. Haverkamp
Electrophysiologic Characterization of the Antipsychotic Drug Sertindole in a Rabbit Heart Model of Torsade de Pointes: Low Torsadogenic Potential Despite QT Prolongation
J. Pharmacol. Exp. Ther.,
January 1, 2002;
300(1):
64 - 71.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. XIBERAS, J. L. MARTINOT, L. MALLET, E. ARTIGES, C. LOC'H, B. MAZIERE, and M. L. PAILLERE-MARTINOT
Extrastriatal and striatal D2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia
The British Journal of Psychiatry,
December 1, 2001;
179(6):
503 - 508.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Mortimer
First-line atypical antipsychotics for schizophrenia are appropriate - with psychosocial interventions
Psychiatr. Bull.,
August 1, 2001;
25(8):
287 - 288.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kapur and P. Seeman
Does Fast Dissociation From the Dopamine D2 Receptor Explain the Action of Atypical Antipsychotics?: A New Hypothesis
Am J Psychiatry,
March 1, 2001;
158(3):
360 - 369.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
D. Taylor
Low dose typical antipsychotics - a brief evaluation
Psychiatr. Bull.,
December 1, 2000;
24(12):
465 - 468.
[Full Text]
|
|
|
|
|
|
|
The Parkinson Study Group
Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
N. Engl. J. Med.,
March 11, 1999;
340(10):
757 - 763.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Truffinet, C. A. Tamminga, L. F. Fabre, H. Y. Meltzer, M.-E. Rivière, and C. Papillon-Downey
Placebo-Controlled Study of the D4/5-HT2A Antagonist Fananserin in the Treatment of Schizophrenia
Am J Psychiatry,
March 1, 1999;
156(3):
419 - 425.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. Kapur, R. B. Zipursky, and G. Remington
Clinical and Theoretical Implications of 5-HT2 and D2 Receptor Occupancy of Clozapine, Risperidone, and Olanzapine in Schizophrenia
Am J Psychiatry,
February 1, 1999;
156(2):
286 - 293.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. R. MARDER, R. LIBERMAN, P. WANG, and D. A. ZARIN
Dr. Marder and Colleagues Reply
Am J Psychiatry,
September 1, 1998;
155(9):
1302 - 1302.
[Full Text]
|
|
|
|
|
|
|
R. BALON
Sertindole versus haloperidol for schizophrenia.
Am J Psychiatry,
September 1, 1998;
155(9):
1303 - 1303.
[Full Text]
|
|
|
|
|
|
|
D. Rampe, M. K. Murawsky, J. Grau, and E. W. Lewis
The Antipsychotic Agent Sertindole is a High Affinity Antagonist of the Human Cardiac Potassium Channel HERG
J. Pharmacol. Exp. Ther.,
August 1, 1998;
286(2):
788 - 793.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. Peet
Sertindole controlled symptoms of schizophrenia without motor side effects
Evid. Based Ment. Health,
February 1, 1998;
1(1):
16 - 16.
[Full Text]
|
|
|
|
|
|
|
{blacktriangledown}Olanzapine, {blacktriangledown}sertindole and schizophrenia
DTB,
November 1, 1997;
35(11):
81 - 83.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Keith
Pharmacologic Advances in the Treatment of Schizophrenia
N. Engl. J. Med.,
September 18, 1997;
337(12):
851 - 852.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1997
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
